Wenda Li
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis 6
- Liver physiology and pathology 3
- Developmental Neuroscience top 10%
-
- MicroRNA in disease regulation 3
-
- Pediatric Hepatobiliary Diseases and Treatments 3
- Cholangiocarcinoma and Gallbladder Cancer Studies 3
-
- RNA modifications and cancer 3
- Glycosylation and Glycoproteins Research 2
-
- Gallbladder and Bile Duct Disorders 3
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Wenda Li
20 papers receiving 546 citations
Peers
Comparison fields: 5 of 62
- Hepatology 153
- Developmental Neuroscience 45
- Oncology 199
- Critical Care and Intensive Care Medicine 37
- Cancer Research 106
Countries citing papers authored by Wenda Li
This map shows the geographic impact of Wenda Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenda Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenda Li more than expected).
Fields of papers citing papers by Wenda Li
This network shows the impact of papers produced by Wenda Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenda Li. The network helps show where Wenda Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Wenda Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2020 | 45 | |
| 3 | 2020 | 6 | |
| 4 | Down-regulation of PCK2 inhibits the invasion and metastasis of laryngeal carcinoma cells. | 2020 | 9 |
| 5 | 2019 | 66 | |
| 6 | 2019 | 12 | |
| 7 | 2019 | 20 | |
| 8 | 2018 | 27 | |
| 9 | 2018 | 85 | |
| 10 | 2018 | 14 | |
| 11 | 2018 | 31 | |
| 12 | 2017 | 23 | |
| 13 | 2017 | 31 | |
| 14 | 2016 | 9 | |
| 15 | 2016 | 31 | |
| 16 | Dose-dependent effects of sevoflurane exposure during early lifetime on apoptosis in hippocampus and neurocognitive outcomes in Sprague-Dawley rats. | 2016 | 28 |
| 17 | 2014 | 1 | |
| 18 | 2014 | 46 | |
| 19 | 2014 | 38 | |
| 20 | [Laparoscopic hepatectomy for recurrent hepatocellular carcinoma after previous open hepatectomy]. | 2014 | 1 |
About Wenda Li
Wenda Li is a scholar working on Hepatology, Developmental Neuroscience and Critical Care and Intensive Care Medicine, having authored 21 papers that have together received 551 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Liver physiology and pathology (3 papers), Pediatric Hepatobiliary Diseases and Treatments (3 papers), MicroRNA in disease regulation (3 papers), RNA modifications and cancer (3 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Gallbladder and Bile Duct Disorders (3 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Hepatology (153 citations), Developmental Neuroscience (45 citations) and Oncology (199 citations). Wenda Li has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Changzhen Shang, Wenliang Tan, Yajin Chen, Jinyi Zhong, Xue Zhou, Zejian Huang, Rui Zhou, Yajin Chen, Dihan Lu and Jun Cao.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.